Ken Cacciatore
Stock Analyst at TD Cowen
(0.30)
# 4,284
Out of 5,005 analysts
13
Total ratings
27.27%
Success rate
-28.39%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $19.92 | +151.00% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $6.68 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.60 | +36.99% | 4 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $5.67 | +340.92% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $15.20 | +130.26% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.71 | +1,247.71% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $4.96 | +908.06% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $15.81 | +184.63% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $18.84 | +2,341.61% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $19.92
Upside: +151.00%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.68
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.60
Upside: +36.99%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $5.67
Upside: +340.92%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $15.20
Upside: +130.26%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.71
Upside: +1,247.71%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $4.96
Upside: +908.06%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $15.81
Upside: +184.63%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $18.84
Upside: +2,341.61%